News | April 10, 2009

SCAI Hosts Scientific Sessions May 6-9 in Las Vegas

April 10, 2009 - The Society for Cardiovascular Angiography and Interventions (SCAI) will host its annual scientific sessions May 6-9 in Las Vegas, NV.

This year’s meeting will highlight the latest research and hottest topics in interventional cardiology. Highlights will include late-breaking clinical trials, including the AMADEUS trial on percutaneous mitral valve repair and new results from The Clopidogrel Medco Outcomes Study on the effects of clopidogrel and individual PPIs. Practice-changing trials and abstracts sessions will review how the major trials of the past 12 months impact patient care, including SYNTAX, FREEDOM and others.

Keynote addresses include simplifying approval of children’s devices by Charles E. Mullins, M.D., FSCAI, what the latest studies say about utilization of angioplasty by Paul Teirstein, M.D., and the qualities that comprise professionalism in medicine by Christopher J. White, M.D., FSCAI.

The event also includes emerging technology and therapy sessions on future stent technology, percutaneous valve technology and antiplatelet drugs. Live cases will be presented on a variety of topics, including left main and bifurcation, structural heart disease, and others.

Other key themes of research to be presented include structural heart disease, radial versus femoral PCI, inpatient versus outpatient PCI, disparities between men and women, and treatment of octogenarians.

For more information:

Related Content

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init